Literature DB >> 23925627

BRAF V600E mutation and papillary thyroid cancer.

Mingzhao Xing.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23925627      PMCID： PMC3779839          DOI： 10.1001/jama.2013.8592

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  4 in total

1.  Molecular testing in thyroid cancer: BRAF mutation status and mortality.

Authors:  Anne R Cappola; Susan J Mandel
Journal:  JAMA       Date:  2013-04-10       Impact factor: 56.272

2.  The BRAF(V600E) mutation is an independent, poor prognostic factor for the outcome of patients with low-risk intrathyroid papillary thyroid carcinoma: single-institution results from a large cohort study.

Authors:  Rossella Elisei; David Viola; Liborio Torregrossa; Riccardo Giannini; Cristina Romei; Clara Ugolini; Eleonora Molinaro; Laura Agate; Agnese Biagini; Cristiana Lupi; Laura Valerio; Gabriele Materazzi; Paolo Miccoli; Paolo Piaggi; Aldo Pinchera; Paolo Vitti; Fulvio Basolo
Journal:  J Clin Endocrinol Metab       Date:  2012-10-12       Impact factor: 5.958

3.  BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer.

Authors:  Mingzhao Xing; Douglas Clark; Haixia Guan; Meiju Ji; Alan Dackiw; Kathryn A Carson; Matthew Kim; Anthony Tufaro; Paul Ladenson; Martha Zeiger; Ralph Tufano
Journal:  J Clin Oncol       Date:  2009-05-04       Impact factor: 44.544

4.  Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer.

Authors:  Mingzhao Xing; Ali S Alzahrani; Kathryn A Carson; David Viola; Rossella Elisei; Bela Bendlova; Linwah Yip; Caterina Mian; Federica Vianello; R Michael Tuttle; Eyal Robenshtok; James A Fagin; Efisio Puxeddu; Laura Fugazzola; Agnieszka Czarniecka; Barbara Jarzab; Christine J O'Neill; Mark S Sywak; Alfred K Lam; Garcilaso Riesco-Eizaguirre; Pilar Santisteban; Hirotaka Nakayama; Ralph P Tufano; Sara I Pai; Martha A Zeiger; William H Westra; Douglas P Clark; Roderick Clifton-Bligh; David Sidransky; Paul W Ladenson; Vlasta Sykorova
Journal:  JAMA       Date:  2013-04-10       Impact factor: 56.272
  4 in total
  9 in total

Review 1.  MicroRNAs in the thyroid.

Authors:  Myriem Boufraqech; Joanna Klubo-Gwiezdzinska; Electron Kebebew
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2016-11-01       Impact factor: 4.690

2.  Tumor mutation burden-assisted risk stratification for papillary thyroid cancer.

Authors:  Zhijiang Chen; Weiran Wang; Jiajie Xu; Yuntao Song; Honglin Zhu; Tonghui Ma; Minghua Ge; Haixia Guan
Journal:  Endocrine       Date:  2022-08-12       Impact factor: 3.925

3.  Relationship of body mass index with BRAF (V600E) mutation in papillary thyroid cancer.

Authors:  Rong-Liang Shi; Ning Qu; Tian Liao; Wen-Jun Wei; Zhong-Wu Lu; Ben Ma; Yu-Long Wang; Qing-Hai Ji
Journal:  Tumour Biol       Date:  2016-01-05

4.  Aberrant expression of COT is related to recurrence of papillary thyroid cancer.

Authors:  Jandee Lee; Seonhyang Jeong; Jae Hyun Park; Cho Rok Lee; Cheol Ryong Ku; Sang-Wook Kang; Jong Ju Jeong; Kee-Hyun Nam; Dong Yeob Shin; Eun Jig Lee; Woong Youn Chung; Young Suk Jo
Journal:  Medicine (Baltimore)       Date:  2015-02       Impact factor: 1.889

5.  BRAF Mutations in an Italian Regional Population: Implications for the Therapy of Thyroid Cancer.

Authors:  Eleonora Monti; Michela Bovero; Lorenzo Mortara; Giorgia Pera; Simonetta Zupo; Elena Gugiatti; Mariella Dono; Barbara Massa; Gian Luca Ansaldo; Giusti Massimo
Journal:  Int J Endocrinol       Date:  2015-11-26       Impact factor: 3.257

6.  Genomic Profiling of Thyroid Nodules: Current Role for ThyroSeq Next-Generation Sequencing on Clinical Decision-Making.

Authors:  Atil Y Kargi; Marcela Perez Bustamante; Seza Gulec
Journal:  Mol Imaging Radionucl Ther       Date:  2017-02-09

7.  The rs2910164 Genetic Variant of miR-146a-3p Is Associated with Increased Overall Mortality in Patients with Follicular Variant Papillary Thyroid Carcinoma.

Authors:  Marta Kotlarek; Anna Kubiak; Małgorzata Czetwertyńska; Michał Świerniak; Wojciech Gierlikowski; Monika Kolanowska; Elwira Bakuła-Zalewska; Sissy M Jhiang; Krystian Jażdżewski; Anna Wójcicka
Journal:  Int J Mol Sci       Date:  2018-02-26       Impact factor: 5.923

8.  MFAP2 is a Potential Diagnostic and Prognostic Biomarker That Correlates with the Progression of Papillary Thyroid Cancer.

Authors:  Si Yang Dong; Hao Chen; Li Zhi Lin; Lingli Jin; Dan Xiang Chen; Ou Chen Wang; Zhi Qiang Ye
Journal:  Cancer Manag Res       Date:  2020-12-07       Impact factor: 3.989

9.  The expression of stromal biomarkers in small papillary thyroid carcinomas.

Authors:  Haytham Bayadsi; George Barghout; Moa Gustafsson; Malin Sund; Joakim Hennings
Journal:  World J Surg Oncol       Date:  2022-10-14       Impact factor: 3.253
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.